Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Nuvasive - You Need To See This

3 MedTech Stocks to Grab Now for a Strong 2025

This article highlights three MedTech stocks poised for growth in 2025

Would you have your legs broken to make yourself taller? The men who go through hell for a little extra height

Would you have your legs broken to make yourself taller? The men who go through hell for a little extra height

The procedure can cost £80,000 – but increasing numbers of people are putting themselves through leg-lengthening surgery. What drives them to do it? And is it worth the pain and potential complications?

The Guardian - UK

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

NuVasive Earnings Perspective: Return On Invested Capital

According to Benzinga Pro, during Q1, NuVasive (NASDAQ:NUVA) earned $19.20 million, a 152.27% increase from the preceding quarter. NuVasive's sales decreased to $290.76 million, a 3.75% change since Q4.

4 Analysts Have This to Say About NuVasive

Analysts have provided the following ratings for NuVasive (NASDAQ:NUVA) within the last quarter:

NuVasive: Q1 Earnings Insights

NuVasive (NASDAQ:NUVA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:10 PM. Here's what investors need to know about the announcement. Earnings NuVasive beat estimated earnings by 38.46%, reporting an EPS of $0.54 versus an estimate of $0.39.

Earnings Outlook For NuVasive

NuVasive (NASDAQ:NUVA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that NuVasive will report an earnings per share (EPS) of $0.39.

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2022

NuVasive: Q4 Earnings Insights

NuVasive: Q4 Earnings Insights

NuVasive (NASDAQ:NUVA) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings NuVasive missed estimated earnings by 16.67%, reporting an EPS of $0.4 versus an estimate of $0.48.

1

Organisations

Bank of America

Abbott Laboratories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

380,252 stories

140,319 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play